Why is Shattuck Labs stock slipping today?
Shattuck Labs (STTK) shares fell 1.8% pre-open after its Q2 2026 earnings. The company reported a net loss of $15.2 million versus $12.5 million a year earlier, and R&D rose 34% to $11.7 million. It cited favorable Phase 1 safety for SL-325 and said Phase 2b in Crohn’s is on track. Cash and investments were about $208.3 million.
How this was made
The 30-second read
Why it matters
For STTK, the earnings section provides the immediate negative catalyst (net loss, R&D up, no revenue beat), while the clinical section provides a medium-term offset (SL-325 safety/durability and Phase 2b on-track timing).
Market read
STTK is trading near its 52-week high after earnings that lacked revenue upside, but investors are also digesting supportive early clinical durability and stated Phase 2b timing.
What to watch
The article does not quantify guidance, cash burn trajectory, or probability of Phase 2 success; traders may need to verify whether the cash runway and trial design reduce dilution risk.
Background
The piece attributes Shattuck Labs’ pre-open decline to its Q2 2026 earnings and cost increase, while highlighting constructive Phase 1 clinical updates for SL-325 and a new candidate SL-846.
Ticker impact
Shattuck Labs reported Q2 2026 net loss of $15.2M and higher R&D, while Phase 1 SL-325 data supported Phase 2b start this quarter.
Near-term downside risk from the earnings miss and R&D increase, partially offset by improved pipeline read-through and stated Phase 2b timing.
The article’s immediate driver for the pre-open dip is the earnings snapshot (net loss, no revenue beat, R&D up 34%), while the most concrete offset is SL-325 Phase 1 durability and the claim that RECEPTIVE-CD1 Phase 2b is on track to begin this quarter.
Market effects
Small-cap biotech sentiment appears cautious, with investors weighing cost growth and lack of revenue against early clinical signals.
US indices were slightly positive (S&P 500 +0.1%, Nasdaq +0.3%), suggesting company-specific factors dominated.
Limited, as the catalyst is company-specific clinical and earnings information.
Counterpoint
The earnings miss may be less important than the pipeline timing, so dips could be viewed as an opportunity if Phase 2b initiation proceeds as stated.
Key entities
- companyShattuck Labs
Clinical-stage biotech whose Q2 2026 earnings and Phase 1 SL-325 data are cited as drivers of today’s pre-open move.
- drug_candidateSL-325
Lead DR3-blocking antibody; Phase 1 data show favorable safety and durable receptor blockade over three months at therapeutic doses.
- clinical_trialRECEPTIVE-CD1
Phase 2b Crohn’s disease trial referenced as on track to begin in the current quarter.
- drug_candidateSL-846
Half-life extended bispecific antibody candidate; Phase 1 data anticipated in 2027.
